Critically ill patients with cirrhosis and acute-on-chronic liver failure (ACLF) exhibit high in-hospital mortality when treated with continuous renal replacement therapy (CRRT).
Higher prescribed CRRT dose (>30 mL/kg/hr) is independently associated with increased mortality, suggesting careful dosing optimization is necessary.
Regional citrate anticoagulation is commonly utilized despite historical concerns about citrate toxicity in cirrhotic patients.
Most ICU survivors transition from CRRT to intermittent hemodialysis prior to hospital discharge, indicating the trajectory of renal recovery and dialysis management in this population.
